The Janus faces of adrenoceptors: Factors controlling the coupling of adrenoceptors to multiple signal transduction pathways

被引:9
作者
Summers, RJ [1 ]
Broxton, N [1 ]
Hutchinson, DS [1 ]
Evans, BA [1 ]
机构
[1] Monash Univ, Dept Pharmacol, Mol Pharmacol Lab, Clayton, Vic 3800, Australia
关键词
A61603; adenylate cyclase; adrenoceptor; beta(3)-adrenoceptor; alpha(1A)-adrenoceptor; CL316243; cytosensor microphysiometer; oxymetazoline; SR59230A;
D O I
10.1111/j.1440-1681.2004.04094.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The adrenoceptors; (AR) are an important subfamily of rhodopsin-like G-protein-coupled receptors that couple to an increasingly large number of signalling mechanisms. Two important factors that determine the pathways that are used are the C-terminal region of the receptor and the agonist used to activate the receptor. 2. Studies of splice variants of the mouse beta(3)-AR showed that the C-terminus is a factor controlling the signalling characteristics. Although these receptors differ only at the C-terminus, the beta(3b)-AR coupled to both G(s) and G(i), whereas the beta(3a)-AR coupled solely to G(s). 3. Examination of four splice variants of the human alpha(1a)-AR showed that all were able to couple to pertussis toxin-sensitive G-proteins, even though they have radically different C-terminal regions. 4. Comparison of the effects of the beta(3)-AR ligands CL316243 and SR59230A showed that both can activate the mouse beta(3)-AR but that SR59230A uses pathways other than cAMP accumulation in 3T3-F442A cells. 5. Examination of a series of alpha(1)-AR agonists for their ability to activate a number of signalling pathways revealed that A61603 acted as a full agonist in all assays, whereas oxymetazoline was unable to cause cAMP accumulation, suggesting agonist-selective signalling at the human alpha(1A)-AR.
引用
收藏
页码:822 / 827
页数:6
相关论文
共 36 条
  • [1] Evidence against β3-adrenoceptors or low affinity state of β1-adrenoceptors mediating relaxation in rat isolated aorta
    Brahmadevara, N
    Shaw, AM
    MacDonald, A
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2003, 138 (01) : 99 - 106
  • [2] Brink CB, 2000, J PHARMACOL EXP THER, V294, P539
  • [3] Molecular cloning, genomic characterization and expression of novel human α1A-adrenoceptor isoforms
    Chang, DJ
    Chang, TK
    Yamanishi, SS
    Salazar, FHR
    Kosaka, AH
    Khare, R
    Bhakta, S
    Jasper, JR
    Shieh, IS
    Lesnick, JD
    Ford, APDW
    Daniels, DV
    Eglen, RM
    Clarke, DE
    Bach, C
    Chan, HW
    [J]. FEBS LETTERS, 1998, 422 (02) : 279 - 283
  • [4] DIFFERENTIAL INTERACTION OF BETA(1)-ADRENERGIC AND BETA(3)-ADRENERGIC RECEPTORS WITH G(I) IN RAT ADIPOCYTES
    CHAUDHRY, A
    MACKENZIE, RG
    GEORGIC, LM
    GRANNEMAN, JG
    [J]. CELLULAR SIGNALLING, 1994, 6 (04) : 457 - 465
  • [5] CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061
  • [6] Truncated isoforms inhibit [3H]prazosin binding and cellular trafficking of native human α1A-adrenoceptors
    Cogé, F
    Guenin, SP
    Renouard-Try, A
    Rique, H
    Ouvry, C
    Fabry, N
    Beauverger, P
    Nicolas, JP
    Galizzi, JP
    Boutin, JA
    Canet, E
    [J]. BIOCHEMICAL JOURNAL, 1999, 343 : 231 - 239
  • [7] Switching of the coupling of the beta(2)-adrenergic receptor to different G proteins by protein kinase A
    Daaka, Y
    Luttrell, LM
    Lefkowitz, RJ
    [J]. NATURE, 1997, 390 (6655) : 88 - 91
  • [8] Human cloned α1A-adrenoceptor isoforms display α1L-adrenoceptor pharmacology in functional studies
    Daniels, DV
    Gever, JR
    Jasper, JR
    Kava, MS
    Lesnick, JD
    Meloy, TD
    Stepan, G
    Williams, TJ
    Clarke, DE
    Chang, DJ
    Ford, APDW
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 370 (03) : 337 - 343
  • [9] Devic E, 2001, MOL PHARMACOL, V60, P577
  • [10] Influence of β-adrenoceptor agonists on the pulmonary circulation.: Effects of a β3-adrenoceptor antagonist, SR 59230A
    Dumas, M
    Dumas, JP
    Bardou, M
    Rochette, L
    Advenier, C
    Giudicelli, JF
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 348 (2-3) : 223 - 228